16:51 , Apr 19, 2019 |  BC Week In Review  |  Clinical News

Promethera's HepaStem cell therapy safe in liver failure study

Promethera said its HepaStem cell therapy comprising human adult liver-derived mesenchymal stem cells achieved a positive safety profile and improved three measures of liver disease severity in a Phase IIa trial to treat acute-on-chronic liver...
21:37 , Feb 14, 2019 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: January 2019

New Therapeutic Targets and Biomarkers: January 2019 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during January. Therapeutic targets are defined as any protein, gene or other molecule...
00:06 , Jan 23, 2019 |  BC Innovations  |  Distillery Techniques

Drug delivery

TECHNOLOGY: Nanoparticles; polymers A fibrin gel-nanoparticle system could be used to deliver anti-CD47 antibodies to treat cancer. The system consists of a fibrin-based polymer gel containing fibrinogen, thrombin and calcium carbonate nanoparticles that is loaded...
13:47 , Jan 3, 2019 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer Patient sample, cell culture and mouse studies suggest inhibiting FGL1 alone or in combination with PD-L1 inhibition could help treat colorectal cancer. In tumor samples from patients with colorectal cancer, levels of...
21:19 , Oct 15, 2018 |  BC Extra  |  Preclinical News

mAb blocks fibrin's inflammation without clotting interference to treat MS, Alzheimer's

Gladstone Institutes researchers developed a mAb that could help treat neurodegenerative and autoimmune CNS diseases such as multiple sclerosis or Alzheimer's disease by specifically blocking the proinflammatory effects of fibrin without compromising its clotting ability....
19:27 , Sep 10, 2018 |  BC Innovations  |  Distillery Techniques

Drug delivery

TECHNOLOGY: Nanoparticles Nanoparticles bound to red blood cells (RBCs) could be used to deliver drugs to the vasculature of specific organs. The method involves mixing bare nanogels with ex vivo RBCs to enable RBC-nanoparticle binding,...
17:25 , Feb 16, 2018 |  BC Week In Review  |  Clinical News

Ergomed's PeproStat meets in Phase II for intraoperative surgical bleeding

In October, Ergomed plc (LSE:ERGO) reported top-line data from a Phase II trial to treat intraoperative surgical bleeding in 169 patients undergoing liver/soft tissue, vascular or spinal surgery showing that PeproStat met the primary endpoint...
20:33 , Nov 6, 2017 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease

INDICATION: Multiple sclerosis (MS) Patient sample and mouse studies suggest inhibiting fibrinogen could help treat MS. In postmortem brain tissue samples from MS patients, levels of perivascular fibrinogen were higher in chronic MS lesions than...
15:08 , Sep 1, 2017 |  BC Week In Review  |  Clinical News

Ergomed completes enrollment in Ph IIb of PeproStat

Ergomed plc (LSE:ERGO) completed enrollment of >160 patients undergoing liver, soft tissue, vascular or spinal surgery in a Phase IIb trial of PeproStat to treat intraoperative surgical bleeding. The primary endpoint for the double-blind, placebo-controlled,...
23:27 , Aug 17, 2017 |  BC Innovations  |  Targets & Mechanisms

GRP-THINK AT THE BBB

Biogen Inc. has discovered antibodies in patients with a rare CNS autoimmune disease that could provide a new way to deliver mAbs across the blood-brain barrier, an application with wide-reaching ramifications for neurologic drug development....